Hey readers! Here's something that might reframe how you think about a type 1 diagnosis: for most kids, it doesn't have to arrive as an emergency. This week, an international group of experts laid out how to catch the disease years before the first symptom, and the headline recommendation is that screening could start when a child is just two years old. Let's dig in.
🌍 A new consensus on screening every child, not just high-risk families
International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes is the primary source document, published in Diabetologia on 10 September 2026 and developed through a structured nominal group technique. Its core argument is simple: type 1 diabetes can be detected in early stages, before insulin is needed, by screening for islet autoantibodies (IAbs).
"In this international consensus, we provide guidance on the principles and practice of implementing general population screening for IAbs to diagnose early-stage type 1 diabetes."
– Ziegler et al., Diabetologia 2026
Why this matters: today, a type 1 diagnosis often lands only after metabolic decompensation like diabetic ketoacidosis (DKA), and a substantial fraction of children arrive needing intensive care. Catching the disease process early changes the entire experience, from an ER crisis to an outpatient plan with time to prepare. The statement is endorsed by a broad set of organizations, including ATTD, ADCES, EASD, ISPAD, and IDF-Europe.
👶 Why "general population" is the big shift
International Team of Experts Recommends Systematic Screening of Children for Type 1 Diabetes from the German Center for Diabetes Research explains the reasoning behind the most consequential change: screening only high-risk families is not enough.
Screening only children from high-risk families is insufficient because more than 85% of people newly diagnosed with type 1 diabetes have no family history.
That single statistic is the crux. If you screen only relatives of people who already have T1D, you miss the large majority of future cases. The DZD article also lays out a step-by-step diagnostic pathway and age-based intervals: an initial screen at 2 to 4 years, then again at 6 to 8 years, and again at 10 to 15 years, with flexibility to fit national or regional programs.
"The diagnosis of early-stage diabetes is a step-by-step process: it begins with a sensitive screening test and is confirmed by highly specific second-line tests and a second blood sample. The specific design of the screening programme should be adapted to the respective healthcare system."
– Prof. Anette-Gabriele Ziegler, lead author
The recommendations carry endorsement from 20 professional and patient organizations, which is worth noting: this isn't one society's opinion, it's a coordinated position.
🩺 What screening actually looks like in practice
Type 1 diabetes screening could start at age two under new expert guidance puts the practical details in plain terms for families. A blood test looks for islet autoantibodies, markers of the immune response against insulin-producing cells, and can flag the condition before thirst, weight loss, or dangerously high glucose ever appear.
A key point that's easy to miss: a positive autoantibody result is not a diagnosis. It triggers confirmation on a second sample and a blood glucose assessment before any conclusions or treatment decisions.
"The authors therefore recommend introducing screening only when services can deliver the entire pathway."
This is the compassionate, responsible part of the guidance. A positive screen without follow-up support, monitoring, and specialist advice would cause anxiety without benefit. The consensus uses the established preclinical staging framework: Stage 1 is two or more confirmed autoantibodies with normal glucose, Stage 2 adds dysglycemia, and Stage 3 is clinical diabetes. Structured, family-centered communication and psychosocial support are treated as requirements, not add-ons.
📋 The rest of the picture, in brief
Two more takes round out the screening story, plus a summary worth bookmarking:
New International Consensus: Screening the General Population for Islet Autoantibodies to Detect Early-Stage Type 1 Diabetes offers a clear breakdown of the minimum requirements: validated multi-autoantibody panels (commonly GADA, IA-2A, IAA, ZnT8A), confirmatory testing on a new specimen or independent assay, and clear follow-up pathways.
New international guidance supports broader screening for type 1 diabetes from Breakthrough T1D, which convened the expert group, frames the goal as detecting T1D months or even years before symptoms and reducing DKA risk at diagnosis. – Breakthrough T1D
Taken together, these outline eligibility (who), timing (when), and the support infrastructure (what's needed) that makes screening safe rather than simply available.
💊 Also worth your attention this week
Beyond screening, a few developments in day-to-day management stood out:
GLP-1 drugs like Ozempic may now be an option for a group of patients long left out: the ADA's 2026 Standards of Care (recommendation 8.29) now say adults with type 1 diabetes and obesity, defined as BMI 30 or higher (27.5 for Asian American adults), can be considered for GLP-1 therapy for the first time. The ADA is clear that this is added on top of insulin, not a substitute, and requires safeguards like insulin dose adjustment and continuous glucose monitoring.
Tubeless Automated Insulin Delivery Sustains Blood Sugar Control for a Full Year: a 12-month extension of a randomized trial found adults on the Omnipod 5 raised time in target range by an average of 17.9 percentage points (about 4.3 extra hours a day), with A1c falling from 8.33% to 7.18% and no severe hypoglycemia or DKA reported. Adherence was notably high, though the participants were all experienced French pump users.
Analysis links COVID-19 infection in unvaccinated people to lower subsequent type 1 diabetes risk: a Danish registry study of people under 30 found SARS-CoV-2 infection was associated with a 16% lower risk of later T1D. The authors are candid that this is observational and cannot prove causation, but it's a striking counterpoint to earlier mixed findings. – EASD 2026, Milan
A quick note on framing: this issue centers on screening, management, and access because those are the levers available to families right now. Several cure-directed research items crossed our desk this week too, and while the science is genuinely interesting, we hold that coverage lightly to avoid setting up false timelines.
The throughline of the screening guidance is worth sitting with. For the first time, there's a shared international framework saying that a type 1 diagnosis doesn't have to be a crisis, and that most affected kids won't be caught by family history alone. The catch is that screening only helps when the whole pathway, confirmation, monitoring, and support, is ready to catch people. That's a challenge for health systems, but it's a hopeful one.
Until next time, take care of yourselves and each other.